Is Medical Marijuana a Safe Choice?

48740028_pThe recent death of musician and cultural icon Prince from an overdose of fentanyl has brought attention to what the US Centers for Control and Prevention (CDC) calls an epidemic of opioid overdose deaths, at least half of them from prescription drugs.  Like opioids, marijuana alleviates pain, but it has never been shown to cause a single death. Is legalizing medical marijuana a viable alternative to dangerous drugs?

Marijuana has been used medicinally worldwide for thousands of years. It was recognized as a medicine in the US until 1930. However in 1970, Congress classified it as an illegal “Schedule I” drug: a dangerous drug with high potential for abuse and without any medicinal value.

But times they are a-changin’. Twenty-six states have legalized medical marijuana. The Obama administration has refrained from enforcing federal marijuana laws in these states, and both presidential candidates have said they would do likewise. Four states— Colorado, Oregon, Alaska and Washington—have even legalized recreational marijuana.

The US Drug Enforcement Administration (DEA) has been pressured to re-evaluate marijuana as a safer alternative to drugs used to treat pain, the nausea produced by chemotherapy, and a number of nervous system, emotional and other disorders. Any day now the DEA is expected to render its decision on reclassifying  marijuana as a Schedule II drug, thus legalizing it for medicinal purposes.

But, although safer than pharmaceuticals, medical marijuana is certainly not risk-free.

Short-term, marijuana affects mood, perception, psychomotor coordination, and increases heart rate and heart palpitations. It also suppresses immunity and increases susceptibility to cancer.  Chronic, long-term use has been associated with respiratory damage and cognitive impairments that worsen with increasing years of marijuana use. Chronic use increases risk for depression and schizophrenia, especially in teenagers.

Addiction and dependency are also real possibilities. Recreational drugs are neurotoxins, suppressing (poisoning) certain parts of the nervous system. At the same they over-stimulate production of the “reward” neurotransmitter dopamine. Over time this can lead to dopamine depletion and the inability to feel good without more and more stimulation. A recent study found that nearly 3 out of 10 marijuana users manifested a marijuana use disorder.

Teenagers are especially drawn to experimenting with marijuana, and a recent national survey found that less than half of the youths aged 12-17 they questioned saw “great risk” in smoking marijuana once or twice a week. Yet at this age, when the brain is still developing, the risk for future addiction and cognitive and mental health issues is very great indeed.

Although health risks associated with marijuana go down considerably by the age of thirty, we cannot endorse using marijuana at any age. In the end, it is one more drug that alleviates symptoms while dysregulating cell chemistry and doing nothing to address underlying problems.

References:

  1. US Centers for Disease Control and Prevention. Injury Prevention and Control: Opioid Overdose. March 16, 2016.
  1. Grinspoon L. Marihuana as medicine: a please for reconsideration. Journal of the American Medical Association, June 21, 1995.
  1. Bostwick JM. Blurred boundaries: The therapeutics & politics of medical marijuana. Mayo Clinic Proceedings. February 2012;87(2):172-186.
  1. Hotakainen R. Feds nearing a decision of whether pot has medical potential. McClatchy DC, July 10, 2016.
  1. Hegde VL. Cannabinoid receptor activation leads to massive mobilization of myeloid-derived suppressor cells with potent immunosuppressive properties. European Journal of Immunology. December 2010;40(12):3358-3371.
  1. Tashkin DP. Effects of marijuana smoking on the lung. Annals of the American Thoracic Society. June 2013;19(3):239-247.
  2. Solowij N. Cognitive functioning of long-term heavy cannabis users seeking treatment. Journal of the American Medication Association. March 2002;287(8):1123-1131.
  1. van de Giessen E. Deficits in striatal dopamine release in cannabis dependence. Molecular Psychiatry. March 2016. Accessed online July 11, 2016.
  1. Hasin DS. Prevalence of marijuana use disorders in the United States between 2001-2002 and 2012-2013. Journal of the American Medical Association Psychiatry. Published online December 2015;72(12):1235-1242.
  2. Substance Abuse and Mental Health Services Administration. Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings, page 65.
Share and Enjoy:
  • Print
  • Facebook
  • Twitter
  • email
  • LinkedIn

Leave a Reply

Your email address will not be published.